Sarepta Therapeutics (NasdaqGS:SRPT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker17Good afternoon, welcome to Sarepta's fourth quarter 2025 earnings results call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Ian Estepan, Sarepta's Director of Investor Relations. Please go ahead.Speaker8Thank you, operator, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the fourth quarter of 2025. The press ...

Arcutis Biotherapeutics (NasdaqGS:ARQT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker0Ladies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics Inc's fourth quarter fiscal year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated mes ...

Carlsmed (NasdaqGS:CARL) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker5Ladies and gentlemen, thank you for standing by, and welcome to the Carlsmed fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. I would now like to turn the conference over to your first speaker today, Caroline Corner, Investor Relations. Please go ahead, Caroline.Speaker1Thank yo ...

Urban Outfitters (NasdaqGS:URBN) Q4 2026 Earnings call February 25, 2026 04:30 PM ET Speaker12Good day, ladies and gentlemen, and welcome to the Urban Outfitters, Inc. 3rd quarter fiscal 26 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw ...

ADMA Biologics (NasdaqGM:ADMA) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker4Good afternoon. Welcome to the ADMA Biologics full year 2025 financial results and business update conference call on Wednesday, February 25, 2026. At this time, all participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the ...

RxSight (NasdaqGM:RXST) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker7Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the RxSight fourth quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, followed by the ...

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $205 million, up 6% from Q4 2024, with contribution ex-TAC at $195 million, an increase of 8% year-over-year and 16% excluding political [15][16] - Adjusted EBITDA grew 9% to $84 million, resulting in a 43% margin [17][18] - For the full year 2025, contribution ex-TAC totaled $670 million, a year-over-year increase of 10% or 14% excluding political impacts [14][15] - Net income for Q4 was $123 million, significantly up from $36 million in Q4 2024, primarily due to a one-time tax benefit [17][18] Business Line Data and Key Metrics Changes - CTV contribution ex-TAC grew 32% in Q4 2025, reaching 48% of total contribution ex-TAC, while DV+ grew 4% excluding political, but was below expectations [5][14][15] - DV+ contribution ex-TAC was $101 million, a decrease of 1% year-over-year, indicating a shift in spending from DV+ to CTV [16][19] - The contribution ex-TAC mix for Q4 was 48% CTV, 37% mobile, and 15% desktop [16] Market Data and Key Metrics Changes - CTV is now larger than DV+, marking a significant shift in the company's business model towards streaming [5] - The company noted strong growth from major players in the industry, including LG Ads, Netflix, and Paramount, indicating a broad-based adoption of CTV [5][6] - The company observed accelerated budget reallocation from DV+ into CTV, particularly in Q1 2026 [8][12] Company Strategy and Development Direction - The company is focused on capitalizing on the shift towards streaming and programmatic CTV, which is now seen as a dominant form of video consumption [12][13] - The management emphasized the importance of AI and automation in enhancing the advertising marketplace, positioning the company as a foundational player in the future of digital advertising [10][11] - The company plans to return approximately 50% of free cash flow to shareholders through share repurchases, indicating a strong capital allocation strategy [21][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategic position, citing the ongoing shift to CTV and the expected sustained double-digit growth in CTV advertising [12][13] - The company anticipates contribution ex-TAC growth of 8%-10% for Q1 2026, with CTV expected to surpass 50% of total contribution ex-TAC for the first time [22][23] - Management noted that the first quarter is typically the lowest margin quarter, but expects Adjusted EBITDA margin to exceed 35% for the full year 2026 [23] Other Important Information - The company has a cash balance of $553 million and plans to pay off $205 million in convertible notes at maturity [19][20] - The company is actively testing AI capabilities and making strategic investments to improve efficiencies in its platform [24] Q&A Session Summary Question: Sustainability of CTV Growth - Management noted that CTV growth is broad-based and driven by both large advertisers and performance-oriented SMBs, indicating a sustainable trend [26][27] Question: Risk and Client Relationships - Management confirmed that deep integrations with large CTV players enhance client relationships and reduce investment risks [29] Question: CTV vs. Organic Growth - Management indicated that the shift from DV+ to CTV is significant, with both platforms showing growth, but CTV is expected to continue outperforming [33][34] Question: Future Growth Rates - Management expects CTV to sustain high teens to 20% growth rates, while DV+ may face pressure but has emerging growth areas like mobile apps [47][51] Question: AI and Market Impact - Management believes AI will enhance efficiencies in the ad tech sector without significantly compressing take rates, as value creation remains strong [82][84] Question: Open Path and Market Share - Management stated that Open Path has been successfully integrated and is not an existential threat, with no impact on CTV performance [52][53]

Adagene FY Conference Summary Company Overview - **Company**: Adagene (NasdaqGM:ADAG) - **Focus**: Development of immuno-oncology drugs, specifically targeting microsatellite stable colorectal cancer (MSS-CRC) with low response rates to current therapies [2][3] Key Points and Arguments Drug Development and Efficacy - **Lead Compound**: ADG126, a masked anti-CTLA-4 antibody, is being developed in combination with KEYTRUDA (pembrolizumab) for late-line MSS-CRC without liver metastases [3][4] - **Response Rates**: ADG126 has shown a response rate between 15% and 30% depending on dosage, with a median overall survival of 20 months in the lowest dose cohort [3][5] - **Safety Profile**: The discontinuation rate is less than 10%, with no grade 4 or 5 adverse events reported, indicating a favorable safety margin [5][15] Market Opportunity - **Target Population**: Approximately 10,000 patients in the U.S. represent the MSS-CRC without liver metastases, a challenging tumor type for immuno-oncology agents [12] - **Historical Context**: Current standard of care has a median overall survival of 10-14 months, highlighting the need for more effective treatments [2][11] Collaboration and Funding - **Sanofi Investment**: Sanofi committed to an equity investment of up to $25 million, with the first tranche of $17 million received at $2 per share. This funding supports the ongoing phase 2 trial of ADG126 [6][7] - **Trial Collaboration**: Sanofi will evaluate ADG126 in combination with their bispecific PD-1 IL-15 in over 100 patients with solid tumors [6][7] Competitive Landscape - **CTLA-4 Mechanism**: CTLA-4 therapies like Yervoy (ipilimumab) and Imjudo (tremelimumab) generate close to $4 billion in revenues, indicating a robust market for effective CTLA-4 inhibitors [8][9] - **Differentiation**: ADG126 is positioned as a safer alternative with a better safety margin compared to existing CTLA-4 therapies, which have shown high toxicity [10][76] Future Developments - **Upcoming Data**: Updates on ADG126's efficacy and safety are expected in the coming months, including data from triplet combinations and a phase 2 trial in neoadjuvant colorectal cancer patients [20][23] - **Regulatory Pathway**: Plans for a randomized phase 3 trial focusing on overall survival as the primary endpoint are in discussion with the FDA [62][73] Additional Important Insights - **Combination Potential**: ADG126 is seen as a versatile partner for various combinations beyond PD-1, including potential combinations with VEGF and TGF inhibitors [36][38] - **Strategic Partnerships**: The company aims to pursue more licensing deals and trial collaborations to expand its market reach and evaluate novel regimens [23][24] This summary encapsulates the critical insights from the Adagene FY Conference, highlighting the company's strategic direction, drug development progress, and market potential in the oncology space.

Tucows (NasdaqCM:TCX) Q4 2025 Earnings call February 25, 2026 04:00 PM ET Company ParticipantsDavid Woroch - President and CEONone - Company RepresentativeNoneWelcome to Tucows question and answer dialogue for Q4 2025. David Woroch, President and Chief Executive Officer of Tucows and Tucows Domains, will be responding to your questions. For your convenience, this audio file is also available as a transcript in the investors section of our website, along with our Q4 2025 financial results and updated reports ...

Tucows (NasdaqCM:TCX) Q4 2025 Earnings call February 25, 2026 04:00 PM ET Company ParticipantsDavid Woroch - President and CEONone - Company RepresentativeNoneWelcome to Tucows question and answer dialogue for Q4 2025. David Woroch, President and Chief Executive Officer of Tucows and Tucows Domains, will be responding to your questions. For your convenience, this audio file is also available as a transcript in the investors section of our website, along with our Q4 2025 financial results and updated reports ...